Recursion Pharmaceuticals (RXRX) Q3 2024 earnings summary

Executive summary

• Advanced a diverse clinical pipeline with multiple programs in Phase 2 or later, including first-in-disease opportunities in rare and oncology indications, and achieved positive Phase 2 data for REC-994 in CCM.

• Announced a proposed business combination with Exscientia, expected to close in November 2024, creating a company with over $750M in cash and a runway into 2027.

• Reported a net loss of $95.8 million for Q3 2024, with revenue rising to $26.1 million, primarily from a $30 million Roche milestone.

• Maintained strong partnerships with major pharma (Roche, Genentech, Bayer, Sanofi, Merck KGaA) and tech leaders (NVIDIA, Google Cloud, Tempus, Helix), expanding AI-driven drug discovery capabilities.

• Closed a $216.4 million public offering in June 2024, supporting platform expansion and strategic acquisitions.

Financial highlights

• Ended Q3 2024 with $427.6 million in cash and cash equivalents.

• Q3 2024 revenue was $26.1 million, up from $10.1 million in Q3 2023, driven by partnership revenue and a $30 million Roche milestone.

• Net loss per share was $(0.34) for Q3 2024, compared to $(0.43) in Q3 2023.

• Operating expenses rose to $124.4 million in Q3 2024, with R&D representing 60% of total costs.

• Combined cash position with Exscientia projected to exceed $750M post-merger.

Outlook and guidance

• Anticipates closing the Exscientia merger in Q4 2024, subject to shareholder and regulatory approvals.

• Expects significant business synergies, with a combined cash runway extending into 2027.

• Multiple clinical readouts and regulatory milestones expected in late 2024 and 2025 across the pipeline.

• Management expects continued operating losses and the need for additional capital to advance drug candidates.

• Revenue growth anticipated from ongoing and future milestone payments under strategic partnerships.